Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (32,024,000)	$ (5,431,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	32,000	0
Change in fair value of preferred stock tranche liability	(200,000)	(180,000)
Research and development license expense	5,500,000	3,000,000
Stock-based compensation	3,594,000	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(4,184,000)	0
Accounts payable	1,872,000	0
Accrued expenses and other liabilities	3,183,000	907,000
Due to related party	(8,000)	5,000
Net cash used in operating activities	(22,035,000)	(1,699,000)
Cash flows from investing activities
Purchase of property, plant and equipment	(534,000)	0
Net cash used in investing activities	(534,000)	0
Cash flows from financing activities
Proceeds from issuances of Series A convertible preferred stock		18,000,000
Proceeds from note payable to related party		1,673,000
Repayment of note payable to related party		(1,646,000)
Net cash provided by financing activities		18,027,000
Net (decrease) increase in cash and cash equivalents	(22,569,000)	16,328,000
Cash at the beginning of the period	251,253,000	0
Cash at the end of the period	228,684,000	16,328,000
Supplemental disclosure of noncash investing and financing activities:
Purchase of research and development license not yet paid	5,500,000	3,000,000
Property, plant and equipment in accounts payable and accrued expenses	1,101,000	0
Acquisition of property, plant and equipment funded by landlord	607,000	0
Deferred offering costs not yet paid	$ 128,000	0
Allocation of preferred stock tranche liability		1,050,000
Series A issuance costs not yet paid		$ 430,000